Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells
Authors:
Open Access
- 16 February 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep42728
Abstract
Chemogenomic profiling is a powerful and unbiased approach to elucidate pharmacological targets and the mechanism of bioactive compounds. Until recently, genome-wide, high-resolution experiments of this nature have been limited to fungal systems due to lack of mammalian genome-wide deletion collections. With the example of a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, we demonstrate that the CRISPR/Cas9 system enables the generation of transient homo- and heterozygous deletion libraries and allows for the identification of efficacy targets and pathways mediating hypersensitivity and resistance relevant to the compound mechanism of action.Keywords
This publication has 18 references indexed in Scilit:
- Natural products as probes in pharmaceutical researchJournal of Industrial Microbiology and Biotechnology, 2016
- High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer LiabilitiesCell, 2015
- Mapping the Cellular Response to Small Molecules Using Chemogenomic Fitness SignaturesScience, 2014
- High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functionsMicrobiological Research, 2014
- Genetic Screens in Human Cells Using the CRISPR-Cas9 SystemScience, 2014
- How I treat paroxysmal nocturnal hemoglobinuriaBlood, 2009
- The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignanciesBlood, 2009
- A probability-based approach for the analysis of large-scale RNAi screensNature Methods, 2007
- Genomic profiling of drug sensitivities via induced haploinsufficiencyNature Genetics, 1999
- HETEROGENEITY OF MALIGNANT-CELLS FROM A HUMAN COLONIC-CARCINOMA1981